ProQR Therapeutics (PRQR) said Wednesday that it will receive an additional $8.1 million research grant from Rett Syndrome Research Trust to support its clinical trials of drug candidate AX-2402.
The grant brings the research trust's total funding in ProQR to $9.1 million, ProQR said.
Rett Syndrome is a rare neurodevelopmental disorder that causes a regression of a child's language and motor skills.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments